Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift


Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of β-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of β-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.


  • Richard A Insel
  • Jessica L Dunne
  • Mark A Atkinson
  • Jane L Chiang
  • Dana Dabelea
  • Peter A Gottlieb
  • Carla J Greenbaum
  • Kevan C Herold
  • Jeffrey P Krischer
  • Åke Lernmark
  • Robert E Ratner
  • Marian J Rewers
  • Desmond A Schatz
  • Jay S Skyler
  • Jay M Sosenko
  • Anette-G Ziegler
Enheter & grupper
Externa organisationer
  • Juvenile Diabetes Research Foundation
  • University of Florida
  • American Diabetes Association
  • University of Colorado
  • Benaroya Research Institute
  • Yale University
  • University of South Florida

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Endokrinologi och diabetes
Sidor (från-till)1964-1974
TidskriftDiabetes Care
Utgåva nummer10
StatusPublished - 2015
Peer review utfördJa